LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
OPTH
Optimi Health Corp.
There isn't enough reported data to score OPTH yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
OPTH Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
OPTH's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
OPTH PE Valuation
OPTH has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
OPTH Forward outlook
There aren't enough analyst estimates for OPTH to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus OPTH down 205%.
OPTH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2023 | -$1.31 | +$1.32 |
| Q1 2023 | -$1.31 | +$1.61 |
| Q4 2022 | -$1.55 | +$1.18 |
| Q3 2022 | -$2.12 | +$0.02 |
OPTH is still losing money, but far less than before: $1.37 per share over the past year, against $2.92 at its worst in early 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over OPTH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over OPTH on profitability, with a higher operating margin.
OPTH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $98.7K | -29% |
| Q1 2026 | $70K | +62% |
| Q2 2025 | $138.1K | +58% |
| Q1 2025 | $43.1K | -26% |
| Q4 2024 | $163.6K | +121% |
| Q3 2024 | $40.7K | +190% |
| Q2 2024 | $87.2K | +185% |
| Q1 2024 | $58.3K | +18% |
OPTH's revenue has slid since its 2024 peak: $98,700 last quarter, down 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1523% | -1116 points |
| Q1 2026 | -1364% | +251 points |
| Q2 2025 | -406% | +445 points |
| Q1 2025 | -1615% | +11 points |
| Q4 2024 | -498% | +602 points |
| Q3 2024 | -2744% | +3779 points |
| Q2 2024 | -851% | +2101 points |
| Q1 2024 | -1626% | -1626 points |
OPTH's operating margin was −1523% last quarter, down 1025 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over OPTH on cash generation, producing positive trailing cash flow while its opponent burns cash.
OPTH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | -$1.4M |
| Q1 2026 | -$242.3K | -$188.7K |
| Q4 2025 | -$449.9K | -$217.4K |
| Q3 2025 | -$1M | -$462.4K |
| Q2 2025 | -$603.5K | +$137K |
| Q1 2025 | -$53.6K | +$472.8K |
| Q4 2024 | -$232.5K | +$1.1M |
| Q3 2024 | -$557.6K | +$363.3K |
OPTH has burned cash in almost every quarter: −$4M over the past year, against −$1M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over OPTH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
OPTH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +33% | +1.1M shares |
| 1 year | +33% | +1.1M shares |
| 3 years | +84% | +2M shares |
OPTH has 4M diluted shares, up 33% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
OPTH hasn't bought back shares in the past year.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
OPTH Net Leverage
OPTH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
OPTH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.5 | Oversold |
| Stochastic | 11.4 | Oversold |
OPTH's weekly RSI is 27 (oversold) and its Stochastic is 11 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
OPTH PE vs Healthcare Sector
OPTH has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has stronger trend alignment. LLY is above 5 of 5 weekly averages versus OPTH above 0 of 4.
OPTH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.36 | 35% below |
| 20 week MA | $4.24 | 49% below |
| 50 week MA | $5.63 | 61% below |
| 100 week MA | $5.22 | 58% below |
OPTH is in a downtrend: it's below all four of its weekly moving averages, and 58% below its 100-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over OPTH on returns for 2026, with the stronger performance.
OPTH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $7.20 | $4.70 | -35% |
| 2025 | $4.70 | $7.26 | +54% |
| 2026 YTD | $7.26 | $2.18 | -70% |
OPTH has finished lower in one of the last two years. It's down 70% so far in 2026.